Aelis' cannabis use drug flunks phase 2b, driving Indivior to rethink $100M option

Aelis Farma’s hopes of securing a quick, positive decision on a $100 million option payment have gone up in smoke. The French biotech reported the failure of its phase 2b cannabis use disorder (CUD) study Wednesday, prompting its partner Indivior to say it doesn’t currently expect to exercise its option.